Investments
The Problem
Spine Fusion Intervenes Too Late
Traditional open surgery, and most minimally invasive spine surgery (MISS), treats advanced degeneration with reconstructive fusion. These rigid procedures are associated with adjacent segment disease, rising revision rates, prolonged recovery, and escalating system costs.
The Fusion Problem
Fixing the X-ray, Not the Patient's Functions
Treatment often focuses on correcting imaging findings rather than restoring natural motion and function.
Late Diagnosis and Treatment
Many patients are treated only after significant disc degeneration and disability have already developed.
Dependence on Fusion
Spinal fusion remains the default surgical approach despite the availability of motion-preserving alternatives.
Growing Revision Epidemic
Fusion can increase stress on adjacent levels of the spine, sometimes leading to adjacent segment disease and additional surgeries.
Escalating Costs
Hospital-based spine procedures contribute to rising healthcare costs for patients and the healthcare system.
A Market Ready for Revolution
More than 500,000 lumbar fusion procedures are performed each year in the United States, reflecting a spine market still dominated by late-stage reconstructive surgery.
​
Our strategy is to move spine care upstream — away from fusion and toward earlier intervention with motion-preserving, anatomy-respecting technologies performed in the ambulatory surgery center (ASC) setting.
By treating patients earlier:
-
More patients become procedural candidates
-
Fear of spine surgery decreases
-
Cost barriers decline
If successful, we believe this shift could expand the spine total addressable market (TAM) by more than 3×.
​
We are building the patented technologies, standardized training, and ASC-optimized procedural model to lead that transformation.
The Solution
Motion-Preserving Innovation
We are investing in motion-preserving spine technologies that move beyond traditional articulating ball-and-socket disc replacements toward viscoelastic designs that replicate the shock absorption and multi-directional motion of the natural human disc.
REP™ principles
Our strategy is guided by three core principles that shift spine care away from late-stage reconstructive fusion:
Restore Function
Focus on returning patients to active, pain-free lives through advanced biomimetic solutions
Early Diagnosis and Treatment
Intervene before advanced degeneration requires reconstructive fusion
Preserve Anatomy and Motion
Maintain natural spinal mechanics to prevent adjacent segment disease
Investment Opportunity
Series C Open
More than $95 million has been invested in AxioMed to date to advance the development of its motion-preserving disc replacement technologies. AxioMed is preparing to apply for FDA approval of its anterior lumbar disc in 2026, alongside plans to begin international commercialization.
​
The company is currently raising a Series C financing round, offering investors the opportunity to participate through self-directed IRAs (SDIRAs), enabling potential tax-advantaged or tax-free returns depending on account structure.
Institutional Investors Since 2001
